JW THERAPEUTICS
JW Therapeutics is a developer of cell-based therapy technologies created to revolutionize cancer treatment.The company focuses on development, transformation and promotion of cell-based immunotherapies that uses chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to regulate the body's immune system, enabling doctors to save the lives of cancer patients and improve the quality of life.
JW THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2016-02-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.jwtherapeutics.com
Total Employee:
51+
Status:
Active
Contact:
+ 86-21-50464201
Total Funding:
190 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Google Tag Manager Global Site Tag Euro Microsoft Azure DNS US Privacy User Signal Mechanism
Similar Organizations
Amyloid Solution
Amyloid Solution is a developer of therapy intended to overcome Alzheimer by developing modifying treatments.
Autobahn Therapeutics
Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.
Carrick Therapeutics
Carrick Therapeutics is a developer of cancer therapeutics intended to transform the way cancer is treated.
Cryofocus Biotech
Cryofocus Biotech cryoablation device manufacturer.
Dukaanยฎ
Dukaan is a DIY platform which enables merchants with zero programming skills to set up their e-commerce store using smartphone.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
GenFleet Therapeutics
GenFleet Therapeutics is a biotechnology developer and researcher of molecular pharmaceuticals targeting cancer treatments.
Innovative Cellular Therapeutics
Innovative Cellular Therapeutics is a Shanghai-based biotechnology company engaged in research and development of cell therapy.
Neukio Biotherapeutics
Neukio Biotherapeutics is a developer of allogenic immune cell therapies for treatment of cancer.
Nucros Science & Taste
Nucros is a smart-health solutions provider which links your past, present and future to offer diets.
OBiO Technology
OBiO Technology is providing overall solution of viral based gene therapy CRO services, and CDMO/CMO services.
Periotherapia
Periotherapia is a drug discovery business with triple negative breast cancer as the first indication.
Phico Therapeutics
Phico Therapeutics is a developer of novel platform technology designed to overcome antibacterial resistance.
PolyProx
PolyProx Therapeutics is a developer of a novel class of drug intended to provide new therapies for cancer treatment.
PuREC
PuREC is a developer of a culture technology intended to bring efficacy to the treatment process.
S-Alpha Therapeutics
S-Alpha Therapeutics engages in the research and development of health apps and digital therapeutics.
Shanghai Cell Therapy Group
Shanghai Cell Therapy Group is a provider of cellular diagnosis center combining cellular research and treatment services.
WonDRx
Pronounced as Wonder RX. WonDRx prescription serves as the foundation of connected healthcare, it helps optimize clinical practices.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-07-20 | Syracuse Biopharma | Syracuse Biopharma acquired by JW Therapeutics | N/A |
Investors List
ARCH Venture Partners
ARCH Venture Partners investment in Series B - JW Therapeutics
Loyal Valley Capital
Loyal Valley Capital investment in Series B - JW Therapeutics
CPE
CPE investment in Series B - JW Therapeutics
Temasek Holdings
Temasek Holdings investment in Series B - JW Therapeutics
Juno Therapeutics
Juno Therapeutics investment in Series B - JW Therapeutics
Mirae Asset Global Investments
Mirae Asset Global Investments investment in Series B - JW Therapeutics
CR-CP Life Science Fund
CR-CP Life Science Fund investment in Series B - JW Therapeutics
Sequoia Capital China
Sequoia Capital China investment in Series B - JW Therapeutics
Oriza Holdings
Oriza Holdings investment in Series B - JW Therapeutics
WuXi AppTec
WuXi AppTec investment in Series B - JW Therapeutics
Official Site Inspections
http://www.jwtherapeutics.com Semrush global rank: 6.77 M Semrush visits lastest month: 804
- Host name: 42.159.132.179
- IP address: 42.159.132.179
- Location: Shanghai China
- Latitude: 31.0449
- Longitude: 121.4012
- Timezone: Asia/Shanghai
More informations about "JW Therapeutics"
Overview - JW Therapeutics
JW Therapeutics (HKEX: 2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, and โฆSee details»
JW Therapeutics - Crunchbase Company Profile & Funding
JW Therapeutics is a developer of cell-based therapy technologies created to revolutionize cancer treatment.The company focuses on development, transformation and promotion of cell-based โฆSee details»
JW Therapeutics ่ฏๆๅทจ่ฏบ - LinkedIn
JW Therapeutics is an innovative biotech company focusing on the latest clinical cell therapy technology. It is commited to the development, transformation and promotion of breakthrough โฆSee details»
Corporate Governance | JW Therapeutics
Procedures for Shareholders to Propose a Person for Election as a Director of the CompanySee details»
History - JW Therapeutics
Became the market authorization holder (MAH) for cell therapy product, and entered commercial stageSee details»
JW Therapeutics Company Profile - Office Locations, Competitors โฆ
JW Therapeutics has 5 employees across 4 locations and $90 m in total funding,. See insights on JW Therapeutics including office locations, competitors, revenue, financials, executives, โฆSee details»
JW Therapeutics Announces its Cell Immunotherapy โฆ
Apr 25, 2022 As the first product of JW Therapeutics, Carteyva ® (relmacabtagene autoleucel injection) is a CAR-T product approved as a Category 1 biologics product. It was infused for treatment in the first ...See details»
2seventy bio and JW Therapeutics Announce Strategic Partnership โฆ
Oct 27, 2022 For more information, please visit www.jwtherapeutics.com. About 2seventy bio Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and โฆSee details»
2seventy bio and JW Therapeutics Announce Intent To โฆ
Sep 12, 2023 For more information, please visit www.jwtherapeutics.com. About 2seventy bio. Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the ...See details»
JW Therapeutics Announces its Cell Immunotherapy โฆ
SHANGHAI, CHINA, November 9, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced โฆSee details»
JW Therapeutics Announces Initiation of Clinical Study of โฆ
SHANGHAI, March 8, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and โฆSee details»
JW Therapeutics Acquires Syracuse Biopharma and License to
Jul 20, 2020 Shanghai, China and Emeryville, California, July 20, 2020 โ JW Therapeutics, a clinical stage biopharmaceutical company focused on developing, manufacturing and โฆSee details»
JW Therapeutics Announces 2020 Annual Results
Shanghai, China, March 26, 2020 โ JW Therapeutics (stock code: 2126.HK), a leading cellular immunotherapy company, today announced 2020 annual results.. Business Highlights. 2020 โฆSee details»
JW Therapeutics Announces Exclusive Collaboration with 2seventy โฆ
Jan 2, 2024 JW Therapeutics (HKEx: 2126), an independent innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, is โฆSee details»
JW Therapeutics Announces its Cell Immunotherapy Drugs Have ...
Mar 30, 2023 SHANGHAI, March 29, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing โฆSee details»
JW Therapeutics Announces its Cell Immunotherapy Drugs Have ...
SHANGHAI, Nov. 9, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and โฆSee details»
JW Therapeutics and 2seventy bio Announce Strategic Partnership โฆ
For more information, please visit www.jwtherapeutics.com. About 2seventy bio. Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to โฆSee details»
JW Therapeutics Announces IND Approval for the Clinical Trial of ...
SHANGHAI, Sept. 27, 2021 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an innovative biotechnology company focused on developing, manufacturing and commercializing cell โฆSee details»
JW Therapeutics Announces Two Appointments to Strengthen โฆ
SHANGHAI, CHINA, January 10, 2022 - JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focusing on developing, manufacturing and โฆSee details»
JW Therapeutics Announces Receipt of Breakthrough Therapy โฆ
Apr 3, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell...See details»